While early studies using the SP142 clone detected negligible PD-L1 expression in RMS cells, newer data using the 22C3 antibody demonstrate PD-L1 positivity in 35% of cases, restricted to tumor-associated immune cells, which correlates with improved relapse-free survival in low-stage disease [70]. This evidence concerns the gene CD274 and neoplasm.